Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 17-Apr-24 5:19 PM View:  | Benevich Eric Chief Commercial Officer | Neurocrine Biosciences Inc. (NBIX) | 15-Apr-24 | Planned Private Option Sale | 19,818 | $133.37 | $2,643,020.00 | (33%) 60.6K to 40.78K | |
| 17-Apr-24 5:19 PM View: | Benevich Eric Chief Commercial Officer | Neurocrine Biosciences Inc. (NBIX) | 15-Apr-24 | Option Exercise | 19,818 | $81.21 | $1,609,430.00 | 49% 40.78K to 60.6K | (6%) |
| 03-Apr-24 4:44 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 01-Apr-24 | Planned Private Option Sale | 272 | $137.30 | $37,345.60 | (3%) 7.78K to 7.51K | |
| 03-Apr-24 4:44 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 01-Apr-24 | Option Exercise | 272 | $79.02 | $21,493.40 | 4% 7.51K to 7.78K | (3%) |
| 25-Mar-24 6:02 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 21-Mar-24 | Option Exercise | 5,000 | $103.52 | $517,600.00 | 67% 7.51K to 12.51K | |
| 25-Mar-24 6:02 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 21-Mar-24 | Planned Option Sale | 5,000 | $145.06 | $725,320.00 | (40%) 12.51K to 7.51K | |
| 15-Mar-24 5:33 PM View: | Benevich Eric Chief Commercial Officer | Neurocrine Biosciences Inc. (NBIX) | 14-Mar-24 | Option Exercise | 75,000 | $80.90 | $6,067,630.00 | 184% 40.78K to 115.78K | (6%) |
| 15-Mar-24 5:33 PM View: | Benevich Eric Chief Commercial Officer | Neurocrine Biosciences Inc. (NBIX) | 14-Mar-24 | Planned Private Option Sale | 75,000 | $139.38 | $10,453,400.00 | (65%) 115.78K to 40.78K | |
| 15-Mar-24 5:25 PM View: | Morrow George J Director | Neurocrine Biosciences Inc. (NBIX) | 14-Mar-24 | Option Exercise | 40,000 | $39.79 | $1,591,600.00 | 100% 0 to 40.0K | |
| 15-Mar-24 5:25 PM View: | Morrow George J Director | Neurocrine Biosciences Inc. (NBIX) | 14-Mar-24 | Planned Option Sale | 40,000 | $139.42 | $5,576,710.00 | (100%) 40.0K to 0 | |
| 15-Mar-24 5:15 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 13-Mar-24 | Option Exercise | 3,000 | $106.02 | $318,060.00 | 40% 7.51K to 10.51K | |
| 15-Mar-24 5:19 PM View: | Pops Richard F Director | Neurocrine Biosciences Inc. (NBIX) | 13-Mar-24 | Option Exercise | 23,200 | $42.76 | $992,032.00 | 79% 29.51K to 52.71K | |
| 15-Mar-24 5:19 PM View: | Pops Richard F Director | Neurocrine Biosciences Inc. (NBIX) | 13-Mar-24 | Planned Option Sale | 23,200 | $140.33 | $3,255,620.00 | (44%) 52.71K to 29.51K | |
| 15-Mar-24 5:15 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 13-Mar-24 | Planned Option Sale | 3,000 | $140.14 | $420,419.00 | (29%) 10.51K to 7.51K | |
| 12-Mar-24 6:47 PM View: | Pops Richard F Director | Neurocrine Biosciences Inc. (NBIX) | 11-Mar-24 | Planned Option Sale | 100 | $140.00 | $14,000.00 | (< 1%) 29.61K to 29.51K | |
| 12-Mar-24 6:38 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 11-Mar-24 | Planned Option Sale | 200 | $140.00 | $28,000.00 | (3%) 7.71K to 7.51K | |
| 12-Mar-24 6:38 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 11-Mar-24 | Option Exercise | 200 | $106.02 | $21,204.00 | 3% 7.51K to 7.71K | |
| 12-Mar-24 6:47 PM View: | Pops Richard F Director | Neurocrine Biosciences Inc. (NBIX) | 11-Mar-24 | Option Exercise | 100 | $42.76 | $4,276.00 | < 1% 29.51K to 29.61K | |
| 12-Mar-24 6:38 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 08-Mar-24 | Planned Option Sale | 1,800 | $140.03 | $252,053.00 | (19%) 9.31K to 7.51K | |
| 12-Mar-24 6:38 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 08-Mar-24 | Option Exercise | 1,800 | $106.02 | $190,836.00 | 24% 7.51K to 9.31K | |
| 12-Mar-24 6:47 PM View: | Pops Richard F Director | Neurocrine Biosciences Inc. (NBIX) | 08-Mar-24 | Option Exercise | 1,700 | $42.76 | $72,692.00 | 6% 29.51K to 31.21K | |
| 12-Mar-24 6:47 PM View: | Pops Richard F Director | Neurocrine Biosciences Inc. (NBIX) | 08-Mar-24 | Planned Option Sale | 1,700 | $140.05 | $238,078.00 | (5%) 31.21K to 29.51K | |
| 29-Feb-24 7:02 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 29-Feb-24 | Option Exercise | 273 | $79.02 | $21,572.50 | 4% 7.51K to 7.78K | |
| 29-Feb-24 7:02 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 29-Feb-24 | Planned Option Sale | 273 | $135.51 | $36,994.20 | (4%) 7.78K to 7.51K | |
| 29-Feb-24 6:55 PM View: | Benevich Eric Chief Commercial Officer | Neurocrine Biosciences Inc. (NBIX) | 28-Feb-24 | Option Exercise | 75,000 | $53.67 | $4,025,040.00 | 185% 40.62K to 115.62K | |
| 29-Feb-24 6:55 PM View: | Benevich Eric Chief Commercial Officer | Neurocrine Biosciences Inc. (NBIX) | 28-Feb-24 | Planned Option Sale | 75,000 | $134.69 | $10,101,600.00 | (65%) 115.62K to 40.62K | |
| 29-Feb-24 7:02 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 28-Feb-24 | Planned Private Option Sale | 6,544 | $135.34 | $885,638.00 | (47%) 14.05K to 7.51K | |
| 29-Feb-24 7:02 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 28-Feb-24 | Option Exercise | 6,544 | $79.02 | $517,107.00 | 87% 7.51K to 14.05K | (3%) |
| 29-Feb-24 6:50 PM View: | Norwalk Leslie V Director | Neurocrine Biosciences Inc. (NBIX) | 27-Feb-24 | Option Exercise | 8,000 | $84.95 | $679,600.00 | 100% 0 to 8.0K | |
| 29-Feb-24 6:50 PM View: | Norwalk Leslie V Director | Neurocrine Biosciences Inc. (NBIX) | 27-Feb-24 | Planned Option Sale | 8,000 | $135.67 | $1,085,390.00 | (100%) 8.0K to 0 | |
| 22-Feb-24 5:11 PM View: | Pops Richard F Director | Neurocrine Biosciences Inc. (NBIX) | 20-Feb-24 | Option Exercise | 15,000 | $12.98 | $194,700.00 | 51% 29.51K to 44.51K | |
| 22-Feb-24 5:11 PM View: | Pops Richard F Director | Neurocrine Biosciences Inc. (NBIX) | 20-Feb-24 | Planned Option Sale | 15,000 | $132.47 | $1,987,050.00 | (34%) 44.51K to 29.51K | |
| 15-Feb-24 5:45 PM View: | Lippoldt Darin Chief Legal Officer | Neurocrine Biosciences Inc. (NBIX) | 13-Feb-24 | Private Sale (Planned) | 1,098 | $132.99 | $146,028.00 | (3%) 40.84K to 39.74K | |
| 15-Feb-24 5:35 PM View: | Cooke Julie Chief Human Resources Officer | Neurocrine Biosciences Inc. (NBIX) | 13-Feb-24 | Private Sale (Planned) | 796 | $133.04 | $105,902.00 | (4%) 18.77K to 17.98K | |
| 15-Feb-24 5:38 PM View: | Delaet Ingrid Chief Regulatory Officer | Neurocrine Biosciences Inc. (NBIX) | 13-Feb-24 | Private Sale (Planned) | 716 | $133.04 | $95,252.80 | (9%) 8.22K to 7.51K | |
| 15-Feb-24 5:48 PM View: | Onyia Jude Chief Scientific Officer | Neurocrine Biosciences Inc. (NBIX) | 13-Feb-24 | Private Sale (Planned) | 1,432 | $132.94 | $190,371.00 | (10%) 14.56K to 13.13K | |
| 15-Feb-24 5:33 PM View: | Boyer David W. Chief Corp. Affairs Officer | Neurocrine Biosciences Inc. (NBIX) | 13-Feb-24 | Private Sale (Planned) | 1,811 | $133.07 | $240,996.00 | (27%) 6.71K to 4.89K | |
| 14-Feb-24 5:17 PM View: | Gorman Kevin Charles Chief Executive Officer Director | Neurocrine Biosciences Inc. (NBIX) | 13-Feb-24 | Option Exercise | 5,090 | $39.28 | $199,951.00 | 1% 506.96K to 512.05K | |
| 15-Feb-24 5:40 PM View: | Gano Kyle Chief Business Development Off | Neurocrine Biosciences Inc. (NBIX) | 13-Feb-24 | Private Sale (Planned) | 1,352 | $132.90 | $179,674.00 | (< 1%) 136.52K to 135.17K | |
| 15-Feb-24 5:29 PM View: | Benevich Eric Chief Commercial Officer | Neurocrine Biosciences Inc. (NBIX) | 13-Feb-24 | Private Sale (Planned) | 1,098 | $133.01 | $146,050.00 | (3%) 41.71K to 40.62K | |
| 15-Feb-24 5:27 PM View: | Abernethy Matt Chief Financial Officer | Neurocrine Biosciences Inc. (NBIX) | 13-Feb-24 | Private Sale (Planned) | 1,352 | $132.85 | $179,612.00 | (4%) 32.88K to 31.53K | |
| 15-Feb-24 5:51 PM View: | Roberts Eiry Chief Medical Officer | Neurocrine Biosciences Inc. (NBIX) | 13-Feb-24 | Private Sale (Planned) | 1,114 | $132.96 | $148,122.00 | (4%) 24.83K to 23.72K | |
| 15-Feb-24 5:43 PM View: | Gorman Kevin Charles Chief Executive Officer Director | Neurocrine Biosciences Inc. (NBIX) | 13-Feb-24 | Private Sale (Planned) | 2,832 | $133.02 | $376,700.00 | (< 1%) 517.43K to 514.6K | |
| 08-Feb-24 7:46 PM View: | Boyer David W. Chief Corp. Affairs Officer | Neurocrine Biosciences Inc. (NBIX) | 08-Feb-24 | Sale (Planned) | 1,328 | $135.41 | $179,830.00 | (21%) 6.22K to 4.89K | |
| 08-Feb-24 7:17 PM View: | Gano Kyle Chief Business Development Off | Neurocrine Biosciences Inc. (NBIX) | 08-Feb-24 | Sale (Planned) | 980 | $134.20 | $131,519.00 | (< 1%) 134.93K to 133.95K | |
| 08-Feb-24 7:15 PM View: | Benevich Eric Chief Commercial Officer | Neurocrine Biosciences Inc. (NBIX) | 08-Feb-24 | Sale (Planned) | 980 | $134.19 | $131,509.00 | (2%) 40.61K to 39.63K | |
| 08-Feb-24 7:28 PM View: | Roberts Eiry Chief Medical Officer | Neurocrine Biosciences Inc. (NBIX) | 08-Feb-24 | Sale (Planned) | 980 | $134.21 | $131,522.00 | (4%) 23.7K to 22.72K | |
| 08-Feb-24 7:12 PM View: | Abernethy Matt Chief Financial Officer | Neurocrine Biosciences Inc. (NBIX) | 08-Feb-24 | Sale (Planned) | 980 | $134.21 | $131,529.00 | (3%) 31.29K to 30.31K | |
| 08-Feb-24 7:21 PM View: | Gorman Kevin Charles Chief Executive Officer Director | Neurocrine Biosciences Inc. (NBIX) | 08-Feb-24 | Sale (Planned) | 2,274 | $134.15 | $305,052.00 | (< 1%) 509.24K to 506.96K | |
| 08-Feb-24 7:25 PM View: | Lippoldt Darin Chief Legal Officer | Neurocrine Biosciences Inc. (NBIX) | 08-Feb-24 | Sale (Planned) | 911 | $134.24 | $122,289.00 | (2%) 39.67K to 38.76K |
